Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1149298

	registered interest
	date	15/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of using genomics in healthcare for the diagnosis and treatment of blood cancers.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	569
	answer	answer is ministerial correction date of answer 22/10/2019 answer text <p>Genomic testing is already in use as part of the diagnostic pathway for blood cancer. Through implementation of the NHS Genomic Medicine Service, NHS England and NHS Improvement are ensuring consistent and equitable access to genomic testing.</p><p> </p><p>The NHS Long Term Plan sets out the ambition to embed genomic medicine, including whole genome sequencing, into routine clinical care. It is expected that within the next year whole genome sequencing (WGS) will begin to be available for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and acute myeloid leukaemia.</p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 22/10/2019 13:56:18 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	3960 label Biography information for Henry Smith

1150894

	registered interest
	date	21/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the forthcoming NHS people plan will include a fully costed plan for increasing the cancer workforce.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	2759
	answer	answer is ministerial correction date of answer 29/10/2019 answer text <p>The interim NHS People Plan was published on 3 June 2019 and sets out the type of workforce, and future staff and leadership culture the National Health Service will need to develop, to ensure the successful delivery of the NHS Long Term Plan.</p><p> </p><p>The final NHS People Plan will be informed by the Cancer Workforce Plan for England, published in December 2017 by Health Education England. This set out plans to expand capacity and skills in the cancer workforce, including targeting additional training support for seven priority professions such as clinical radiology, histopathology, oncology and diagnostic and therapeutic radiography. Since 2017 there has been a net increase of 833 full time equivalent staff across the seven priority professions.</p><p> </p><p>The full NHS People Plan will be published in the next few months and will set out a clear framework for collective action on workforce priorities over the next five years.</p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 29/10/2019 12:38:11 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1156063

	registered interest
	date	24/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has to ensure that GPs follow NICE guidance on blood cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	900212
	answer	answer is ministerial correction date of answer 30/10/2019 answer text <p>The National Institute for Health and Care Excellence’s (NICE) clinical guidelines help healthcare professionals deliver the best possible care based on the best available evidence. The guidelines are not mandatory, although healthcare professionals are expected to take them fully into account</p><p><br>NICE’s updated referral guidelines for suspected cancer published in June 2015 could save about 5,000 lives a year, with general practitioners urged to think of cancer sooner and to lower the referral threshold for tests.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 30/10/2019 07:32:29 answering member 4380 label Biography information for Jo Churchill previous answer version 2614 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1171875

	registered interest
	date	20/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Parking
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timetable is for his Department's consultation on eligibility criteria for free hospital parking.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	5395
	answer	answer is ministerial correction date of answer 27/01/2020 answer text <p>The Department is working with the National Health Service to introduce changes to NHS hospital car parking in England from April 2020.</p><p>This will include free parking for frequent outpatient attenders.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 5396 question first answered 27/01/2020 13:28:50 answering member 4362 label Biography information for Edward Argar
	tabling member	3960 label Biography information for Henry Smith

1171876

	registered interest
	date	20/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Parking
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to exempt people undergoing chemotherapy from hospital parking charges.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	5396
	answer	answer is ministerial correction date of answer 27/01/2020 answer text <p>The Department is working with the National Health Service to introduce changes to NHS hospital car parking in England from April 2020.</p><p>This will include free parking for frequent outpatient attenders.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 5395 question first answered 27/01/2020 13:28:50 answering member 4362 label Biography information for Edward Argar
	tabling member	3960 label Biography information for Henry Smith

1171877

	registered interest
	date	20/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people with (a) relapsed diffuse large B-cell lymphoma and (b) children with relapsed acute lymphoblastic leukaemia have received CAR-T therapies in each of the last five years.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	5397
	answer	answer is ministerial correction date of answer 29/01/2020 answer text <p>Chimeric Antigen Receptor T-cell (CAR-T) therapies have been available since November 2018 (acute lymphoblastic leukaemia) and December 2018 (relapsed DLBCL). The first patients were reinfused in January 2019. Therefore, the only data we have for the last five years is for 2019 and 2020. We do not have numbers for people treated in trials.</p><p> </p><p>Number of people with diffuse large B-cell lymphoma that have received CAR-T therapies in each of the last five years:</p><p> </p><table><tbody><tr><td><p>Indication</p></td><td><p>2019</p></td><td><p>2020*</p></td></tr><tr><td><p>Diffuse large B cell lymphoma</p></td><td><p>133</p></td><td><p>Suppressed due to small numbers</p></td></tr></tbody></table><p>Note: *Up to 21 January 2020</p><p> </p><p>Number of children with relapsed acute lymphoblastic leukaemia that have received CAR-T therapies in each of the last five years:</p><p> </p><table><tbody><tr><td><p>Indication</p></td><td><p>2019</p></td><td><p>2020*</p></td></tr><tr><td><p>Acute lymphoblastic leukaemia</p></td><td><p>20</p></td><td><p>Suppressed due to small numbers</p></td></tr></tbody></table><p>Note: *Up to 21 January 2020</p><p> </p><p>We are unable to provide the numbers of people with relapsed diffuse large B-cell lymphoma and children with relapsed acute lymphoblastic leukaemia that have received CAR-T therapy at each Joint Accreditation Committee ISCT-Europe &amp; EBMT (JACIE) accredited treatment centre treatment due to small numbers and the possibility of patients being identified. This will be possible in the future when the number of patients treated increases.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 5398 question first answered 29/01/2020 10:50:10 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1171878

	registered interest
	date	20/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many (a) people with relapsed diffuse large B-cell lymphoma and (b) children with relapsed ALL have received CAR-T therapy at each JACIE accredited treatment centre.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	5398
	answer	answer is ministerial correction date of answer 29/01/2020 answer text <p>Chimeric Antigen Receptor T-cell (CAR-T) therapies have been available since November 2018 (acute lymphoblastic leukaemia) and December 2018 (relapsed DLBCL). The first patients were reinfused in January 2019. Therefore, the only data we have for the last five years is for 2019 and 2020. We do not have numbers for people treated in trials.</p><p> </p><p>Number of people with diffuse large B-cell lymphoma that have received CAR-T therapies in each of the last five years:</p><p> </p><table><tbody><tr><td><p>Indication</p></td><td><p>2019</p></td><td><p>2020*</p></td></tr><tr><td><p>Diffuse large B cell lymphoma</p></td><td><p>133</p></td><td><p>Suppressed due to small numbers</p></td></tr></tbody></table><p>Note: *Up to 21 January 2020</p><p> </p><p>Number of children with relapsed acute lymphoblastic leukaemia that have received CAR-T therapies in each of the last five years:</p><p> </p><table><tbody><tr><td><p>Indication</p></td><td><p>2019</p></td><td><p>2020*</p></td></tr><tr><td><p>Acute lymphoblastic leukaemia</p></td><td><p>20</p></td><td><p>Suppressed due to small numbers</p></td></tr></tbody></table><p>Note: *Up to 21 January 2020</p><p> </p><p>We are unable to provide the numbers of people with relapsed diffuse large B-cell lymphoma and children with relapsed acute lymphoblastic leukaemia that have received CAR-T therapy at each Joint Accreditation Committee ISCT-Europe &amp; EBMT (JACIE) accredited treatment centre treatment due to small numbers and the possibility of patients being identified. This will be possible in the future when the number of patients treated increases.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 5397 question first answered 29/01/2020 10:50:10 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1172698

	registered interest
	date	22/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to reduce the number of people with blood cancer visiting their GP three or more times.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	6642
	answer	answer is ministerial correction date of answer 31/01/2020 answer text <p>In 2020, NHS England and NHS Improvement will continue to roll-out Rapid Diagnostic Centres across the country to upgrade and bring together the latest diagnostic equipment and expertise. They will initially focus on diagnosing cancers where patients often present with non-specific symptoms, such as blood cancer, and may go to their general practitioner many times before being sent for appropriate tests.</p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 31/01/2020 11:10:11 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1180311

	registered interest
	date	25/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pancreatic Cancer: Surrey and Sussex
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of the level of surgery rates for people with pancreatic cancer in Surrey and Sussex and those rates in other areas of England; and what steps his Department plans to take to improve surgery rates in Surrey and Sussex.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	20451
	answer	answer is ministerial correction date of answer 04/03/2020 answer text <p>This information is not available as requested, and so no assessment has been made.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 04/03/2020 16:02:19 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith

1180312

	registered interest
	date	25/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pancreatic Cancer: Surrey and Sussex
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the levels of late diagnosis rates for people with pancreatic cancer in Surrey and Sussex; and what steps he is taking to ensure that people in those counties receive an earlier diagnosis for pancreatic cancer.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	20452
	answer	answer is ministerial correction date of answer 04/03/2020 answer text <p>The latest NHS England data shows that the late diagnosis rates for pancreatic cancer in Surrey and Sussex increased between 2016 and 2017, from 78.2% to 81.9%.</p><p>Early diagnosis rates for pancreatic cancer in England increased by 2.9 percentage points between 2014 and 2017, from 21.0% to 23.9%, and improving early diagnosis of cancer is a top priority for the National Health Service. That is why of one of the core ambitions in the NHS Long Term Plan is to diagnose 75% of cancers at stage 1 or 2 by 2028 to save 55,000 lives a year. Cancer Alliances in England are using the Rapid Diagnostic Cancer model to improve the diagnostic experience for patients who are suspected of having particular cancers including pancreatic cancer.</p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 04/03/2020 15:57:35 answering member 4380 label Biography information for Jo Churchill
	tabling member	3960 label Biography information for Henry Smith